Charles Schwab Investment Management Inc Esperion Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 554,216 shares of ESPR stock, worth $997,588. This represents 0.0% of its overall portfolio holdings.
Number of Shares
554,216
Previous 554,914
0.13%
Holding current value
$997,588
Previous $915,000
33.22%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding ESPR
# of Institutions
211Shares Held
125MCall Options Held
1.68MPut Options Held
949K-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$44.1 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$25.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21.1 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$17.9 Million0.28% of portfolio
-
Two Seas Capital LP Rye, NY6.58MShares$11.9 Million3.65% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $120M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...